Zydus Launches ‘Zyrifa’, a Biosimilar Denosumab to Protect Bone Health in Cancer Patients

Zydus Lifesciences has launched Zyrifa, a biosimilar version of Denosumab 120 mg (sub-cutaneous), used to reduce and delay serious bone-related complications in patients with solid tumours and multiple myeloma. This launch strengthens Zydus’ focus on providing effective and affordable treatments for patients facing advanced stages of cancer where the disease has spread to the bones.

What the Therapy Does

Denosumab is a monoclonal antibody widely used to protect bone health. It helps prevent painful skeletal-related events such as fractures, spinal cord compression, and reduced mobility. These issues commonly occur when cancer metastasises to bones—a condition often seen in breast, prostate, lung, kidney, thyroid, head & neck cancers, and myeloma. Zyrifa is priced at an MRP of ₹12,495, making the treatment more accessible.

Why Bone Metastases Matter

Bone metastases greatly affect a patient’s quality of life. They cause severe pain, limit movement, increase the risk of fractures, and may lead to loss of independence. In advanced breast and prostate cancer, 50–70% of patients develop bone involvement. Similarly, 15–40% of patients with lung, kidney, thyroid, and melanoma also face bone complications over time. Early and effective treatment like Denosumab can reduce these risks.

Zydus’ Commitment to Cancer Care

Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences, said that the goal of launching Denosumab 120 mg SC is to improve access and affordability for cancer patients who need critical care. He added that maintaining mobility and independence is a crucial part of a patient’s fight against cancer.

Zydus has been expanding its biosimilar portfolio across various cancers, including breast, prostate, blood cancers, and several solid tumours. The company also collaborates with diagnostic firms to support comprehensive cancer care.

About Zydus Lifesciences

Zydus Lifesciences is a global life-sciences company focused on improving health and well-being. As of September 30, 2025, the group employs 27,000 people, including 1,500 scientists working on research and innovation. With strong presence in pharmaceuticals and consumer wellness, Zydus is committed to delivering high-quality healthcare solutions that make a meaningful impact.

Read More: Ashok Leyland Share Price in Focus Ahead of Upcoming Dividend Payout Expected on or Before 11 December 2025.

Zydus Lifesciences Share Price Movement

Zydus Lifesciences share price (NSE: ZYDUSLIFE) was trading at ₹934.35, up 1.53%, as of 10:48 am on December 10. The stock opened at ₹926.80 and touched an intraday high of ₹936.45, while the day’s low stood at ₹925.00. The company currently commands a market cap of ₹94,011 crore and trades at a P/E ratio of 19.11. Over the past year, the stock has moved between a 52-week low of ₹795.00 and a 52-week high of ₹1,059.05. Zydus offers a dividend yield of 1.18%, with a quarterly payout of ₹2.76 per share.

Conclusion

The launch of Zyrifa reinforces Zydus’ position as a key player in cancer care. By making Denosumab more affordable and accessible, the company aims to improve outcomes for patients battling serious bone complications caused by advanced cancers.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.